Search results
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Benzinga via Yahoo Finance· 2 hours agoThursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b...
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results By Investing.com
Investing.com· 6 days agoIn a recent earnings call, Lineage Cell Therapeutics (NYSE:LCTX), a biotechnology company...
Americans to get one-time payment from new $250,000 401k settlement
The US Sun· 4 days agoTHOUSANDS of Americans are eligible for a one-time payout of an undisclosed amount following the...
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
Clinical Trials Arena via Yahoo Finance· 1 day agoThe Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene...
Takeda pays AC Immune $100M upfront for Alzheimer's drug as phase 2 readout nears
FierceBiotech· 3 days agoTakeda may be paring back its R&D pipeline in the name of efficiency, but the Japanese pharma has...
Q1 2024 Lineage Cell Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 days agoData is a major driver of value, and that data was notable for several reasons, and I just want to ensure those points are clear for our new and existing shareholders. Last Friday, on behalf ...
The most innovative Mother’s Day campaigns from Dove, MoneyGram, DoorDash & more
The Drum· 6 days agoFrom heartwarming reunions facilitated by DoorDash to MullenLowe planting career opportunities for...
Spyre Therapeutics names Sandra Milligan to board By Investing.com
Investing.com· 1 day agoSpyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focusing on the development of...
The Smartest People in the Room Are All Listening to the Same Podcast
The Wall Street Journal· 6 days agoIt’s a wonky podcast about business history and strategy with four-hour episodes that drop once a...
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines
GuruFocus.com via Yahoo Finance· 6 days agoExpenses: Reduced to $3.0 million in Q1 2024 from $4.2 million in Q1 2023, driven by lower costs across multiple programs. Partnership Developments: Established a new services agreement with ...
